Advertisement

Biomarkers of Cardiovascular Aging

  • Nirankar S. Neki
  • Paramjit S. Tappia
  • Naranjan S. Dhalla
Chapter

Abstract

Aging is a complex phenomenon that exerts a negative impact on the function of different organs including the heart. The life span and the aging state, measured as the decline of functional capacity and stress resistance, are not the same for every individual. Several investigators have attempted to evaluate the relationship between the biological age and chronological age; however, because of the genetic variations, no definitive conclusions can be made. Likewise, various biomarkers based on changes in body function and composition are employed for diagnostic and prognostic measures to understand the biological processes of aging, but no specific marker of aging has yet been identified. Furthermore, risk factors for cardiovascular disease including obesity, hypertension, atherosclerosis, diabetes, myocardial infarction, and cardiac hypertrophy are known to affect the aging process. Since cardiovascular disease is the leading cause of mortality in individuals over 65 years of age, biomarkers such as mediators of oxidative stress, inflammation, and several hormones are considered to be associated with cardiovascular aging. In view of the development of cardiac dysfunction in aging population, there is a need for the identification of possible biomarkers of aging that are independent of comorbidities. Such information may assist in the formulation of new strategies to improve the quality of life and health status of the elderly population.

Keywords

Telomere Length Abdominal Aorta Aneurysm Healthy Aging Natural Killer Cytotoxicity Massachusetts Male Aging Study 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

We thank the St. Boniface Hospital Research Foundation for infrastructural support. N.S.N. was a Visiting Professor from the Government Medical College and Guru Nanak Dev Hospital, Amritsar, India.

References

  1. 1.
    Verbrugge LM, Jette AM. The disablement process. Soc Sci Med. 1994;38:1–14.PubMedGoogle Scholar
  2. 2.
    Schwartz JB, Zipes DP. Cardiovascular disease in the elderly. In: Braunwald E, Zipes DP, Libby P, editors. Heart disease. 8th ed. Philadelphia, PA: WB Saunders; 2007. p. 1925–49.Google Scholar
  3. 3.
    MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronaryheart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765–74.PubMedGoogle Scholar
  4. 4.
    Domanski MJ, Davis BR, Pfeffer MA, et al. Isolated systolic hypertension: prognostic information provided by pulse pressure. Hypertension. 1999;34:375–80.PubMedGoogle Scholar
  5. 5.
    Chae CU, Pfeffer MA, Glynn RJ, et al. Increased pulse pressure and risk of heart failure in the elderly. JAMA. 1999;281:634–9.PubMedGoogle Scholar
  6. 6.
    Mitchell GF, Moyé LA, Braunwald E, et al. Sphygmomanometrically determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function. SAVE investigators. Survival and Ventricular Enlargement. Circulation. 1997;96:4254–60.PubMedGoogle Scholar
  7. 7.
    Baker III GT, Sprott RL. Biomarkers of aging. Exp Gerontol. 1988;23:223–39.PubMedGoogle Scholar
  8. 8.
    De Gruttola VG, Clax P, DeMets DL, et al. Considerations in the evaluation of surrogate endpoints in clinical trials. Summary of a National Institutes of Health workshop. Control Clin Trials. 2001;22:485–502.PubMedGoogle Scholar
  9. 9.
    Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95.Google Scholar
  10. 10.
    National Heart, Lung and Blood Institute. Shaping the future of research: a strategic plan for the National Heart, Lung and Blood Institute. http://www.nhlbi.nih.gov/about/strategicplan/documents/StrategicPlan_Plain.pdf. Accessed 17 Oct 2012.
  11. 11.
    Johnson TE. Recent results: biomarkers of aging. Exp Gerontol. 2006;41:1243–6.PubMedGoogle Scholar
  12. 12.
    Warner HR. Current status of efforts to measure and modulate the biological rate of aging. J Gerontol A Biol Sci Med Sci. 2004;59:692–6.PubMedGoogle Scholar
  13. 13.
    Corriveau H, Hébert R, Raîche M, et al. Postural stability in the elderly: empirical confirmation of a theoretical model. Arch Gerontol Geriatr. 2004;39:163–77.PubMedGoogle Scholar
  14. 14.
    Mazzeo RS, Tanaka H. Exercise prescription for the elderly: current recommendations. Sports Med. 2001;31:809–18.PubMedGoogle Scholar
  15. 15.
    Van Petten C. Relationship between hippocampal volume and memory ability in healthy individuals across the lifespan: review and meta-analysis. Neuropsychologia. 2004;42:1394–413.PubMedGoogle Scholar
  16. 16.
    Hamet P, Tremblay J. Genes of aging. Metabolism. 2003;52 Suppl 2:5–9.PubMedGoogle Scholar
  17. 17.
    Manolio TA. Study designs to enhance identification of genetic factors in healthy aging. Nutr Rev. 2007;65:S228–33.PubMedGoogle Scholar
  18. 18.
    Short KR, Bigelow ML, Kahl J, et al. Decline in skeletal muscle mitochondrial function with aging in humans. Proc Natl Acad Sci USA. 2005;102:5618–23.PubMedGoogle Scholar
  19. 19.
    Harman D. Free radical theory of aging: an update: increasing the functional life span. Ann NY Acad Sci. 2006;1067:10–21.PubMedGoogle Scholar
  20. 20.
    Kirkwood T. Age action. In: Changing expectations of life. Newcastle upon Tyne: Institute of Aging and Health, Newcastle University; 2007.Google Scholar
  21. 21.
    Crimmins E, Vasunilashorn S, Kim JK, Alley D. Biomarkers related to aging in human populations. Adv Clin Chem. 2008;46:161–216.PubMedGoogle Scholar
  22. 22.
    Kannel WB. Sixty years of preventive cardiology: a Framingham perspective. Clin Cardiol. 2011;34:342–3.PubMedGoogle Scholar
  23. 23.
    Januzzi Jr JL, Rehman SU, Mohammed AA, et al. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol. 2011;58:1881–9.PubMedGoogle Scholar
  24. 24.
    de Filippi CR, de Lemos JA, Christenson RH, et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA. 2010;304:2494–502.Google Scholar
  25. 25.
    Knight JA. The biochemistry of aging. Adv Clin Chem. 2003;35:1–62.Google Scholar
  26. 26.
    Loft S, Høgh Danielsen P, Mikkelsen L, et al. Biomarkers of oxidative damage to DNA and repair. Biochem Soc Trans. 2008;36:1071–6.PubMedGoogle Scholar
  27. 27.
    Balaban RS, Nemoto S, Finkel T. Mitochondria, oxidants, and aging. Cell. 2005;120:483–95.PubMedGoogle Scholar
  28. 28.
    Ravanat JL, Di Mascio P, Martinez GR, et al. Singlet oxygen induces oxidation of cellular DNA. J Biol Chem. 2000;275:40601–4.PubMedGoogle Scholar
  29. 29.
    López-Diazguerrero NE, Luna-López A, Gutiérrez-Ruiz MC, et al. Susceptibility of DNA to oxidative stressors in young and aging mice. Life Sci. 2005;77:2840–54.PubMedGoogle Scholar
  30. 30.
    López-Torres M, Gredilla R, Sanz A, Barja G. Influence of aging and long-term caloric restriction on oxygen radical generation and oxidative DNA damage in rat liver mitochondria. Free Radic Biol Med. 2002;32:882–9.PubMedGoogle Scholar
  31. 31.
    Evans MD, Dizdaroglu M, Cooke MS. Oxidative DNA damage and disease: induction, repair and significance. Mutat Res. 2004;567:1–61.PubMedGoogle Scholar
  32. 32.
    Poulsen HE, Loft S, Prieme H, et al. Oxidative DNA damage in vivo: relationship to age, plasma antioxidants, drug metabolism, glutathione-S-transferase activity and urinary creatinine excretion. Free Radic Res. 1998;29:565–71.PubMedGoogle Scholar
  33. 33.
    Loft S, Vistisen K, Ewertz M, et al. Oxidative DNA damage estimated by 8-hydroxydeoxyguanosine excretion in humans: influence of smoking, gender and body mass index. Carcinogenesis. 1992;13:2241–7.PubMedGoogle Scholar
  34. 34.
    Davies MJ, Fu S, Wang H, Dean RT. Stable markers of oxidant damage to proteins and their application in the study of human disease. Free Radic Biol Med. 1999;27:1151–63.PubMedGoogle Scholar
  35. 35.
    Levine RL. Carbonyl modified proteins in cellular regulation, aging, and disease. Free Radic Biol Med. 2002;32:790–6.PubMedGoogle Scholar
  36. 36.
    Dalle-Donne I, Giustarini D, Colombo R, et al. Protein carbonylation in human diseases. Trends Mol Med. 2003;9:169–76.PubMedGoogle Scholar
  37. 37.
    Gil L, Siems W, Mazurek B, et al. Age-associated analysis of oxidative stress parameters in human plasma and erythrocytes. Free Radic Res. 2006;40:495–505.PubMedGoogle Scholar
  38. 38.
    Grune T, Merker K, Sandig G, Davies KJ. Selective degradation of oxidatively modified protein substrates by the proteasome. Biochem Biophys Res Commun. 2003;305:709–18.PubMedGoogle Scholar
  39. 39.
    Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature. 2000;408:239–47.PubMedGoogle Scholar
  40. 40.
    Halliwell B. Biochemistry of oxidative stress. Biochem Soc Trans. 2007;35:1147–50.PubMedGoogle Scholar
  41. 41.
    Montuschi P, Barnes PJ, Roberts II LJ. Isoprostanes: markers and mediators of oxidative stress. FASEB J. 2004;18:1791–800.PubMedGoogle Scholar
  42. 42.
    Slatter DA, Bolton CH, Bailey AJ. The importance of lipid-derived malondialdehyde in diabetes mellitus. Diabetologia. 2000;43:550–7.PubMedGoogle Scholar
  43. 43.
    Uchida K. 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog Lipid Res. 2003;42:318–43.PubMedGoogle Scholar
  44. 44.
    Corti MC, Guralnik JM, Salive ME, et al. Clarifying the direct relation between total cholesterol levels and death from coronary heart disease in older persons. Ann Intern Med. 1997;126:753–60.PubMedGoogle Scholar
  45. 45.
    Manolio TA, Pearson TA, Wenger NK, et al. Cholesterol and heart disease in older persons and women. Review of an NHLBI workshop. Ann Epidemiol. 1992;2:161–76.PubMedGoogle Scholar
  46. 46.
    Colpo A. LDL cholesterol: “Bad” cholesterol or bad science? Am J Phys Surg. 2005;10:83–9.Google Scholar
  47. 47.
    Reed D, Yano K, Kagan A. Lipids and lipoproteins as predictors of coronary heart disease, stroke, and cancer in the Honolulu Heart Program. Am J Med. 1986;80:871–8.PubMedGoogle Scholar
  48. 48.
    Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991;88:1785–92.PubMedCentralPubMedGoogle Scholar
  49. 49.
    Millar JS, Lichtenstein AH, Cuchel M, et al. Impact of age on the metabolism of VLDL, IDL, and LDL apolipoprotein B-100 in men. J Lipid Res. 1995;36:1155–67.PubMedGoogle Scholar
  50. 50.
    Whayne TF, Alaupovic P, Curry MD, et al. Plasma apolipoprotein B and VLDL-, LDL-, and HDL-cholesterol as risk factors in the development of coronary artery disease in male patients examined by angiography. Atherosclerosis. 1981;39:411–24.PubMedGoogle Scholar
  51. 51.
    Linton MF, Fazio S, National Cholesterol Education Program (NCEP)-the third Adult Treatment Panel (ATP III). A practical approach to risk assessment to prevent coronary artery disease and its complications. Am J Cardiol. 2003;92:19i–26.PubMedGoogle Scholar
  52. 52.
    Gaziano JM, Hennekens CH, O’Donnell CJ, et al. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation. 1997;96:2520–5.PubMedGoogle Scholar
  53. 53.
    Serra V, von Zglinicki T, Lorenz M, Saretzki G. Extracellular superoxide dismutase is a major antioxidant in human fibroblasts and slows telomere shortening. J Biol Chem. 2003;278:6824–30.PubMedGoogle Scholar
  54. 54.
    Rea IM, McMaster D, Donnelly J, et al. Malondialdehyde and measures of antioxidant activity in subjects from the Belfast Elderly Longitudinal Free-living Aging Study. Ann NY Acad Sci. 2004;1019:392–5.PubMedGoogle Scholar
  55. 55.
    Berr C, Richard MJ, Gourlet V, et al. Enzymatic antioxidant balance and cognitive decline in aging–the EVA study. Eur J Epidemiol. 2004;19:133–8.PubMedGoogle Scholar
  56. 56.
    Richie Jr JP, Mills BJ, Lang CA. Correction of a glutathione deficiency in the aging mosquito increases its longevity. Proc Soc Exp Biol Med. 1987;184:113–7.PubMedGoogle Scholar
  57. 57.
    Benzi G, Pastoris O, Marzatico F, Villa RF. Age-related effect induced by oxidative stress on the cerebral glutathione system. Neurochem Res. 1989;14:473–81.PubMedGoogle Scholar
  58. 58.
    Jones DP, Mody Jr VC, Carlson JL, et al. Redox analysis of human plasma allows separation of pro-oxidant events of aging from decline in antioxidant defenses. Free Radic Biol Med. 2002;33:1290–300.PubMedGoogle Scholar
  59. 59.
    Byers T, Bowman B. Vitamin E supplements and coronary heart disease. Nutr Rev. 1993;51:333–6.PubMedGoogle Scholar
  60. 60.
    Comstock GW, Helzlsouer KJ, Bush TL. Prediagnostic serum levels of carotenoids and vitamin E as related to subsequent cancer in Washington County, Maryland. Am J Clin Nutr. 1991;53(1 Suppl):260S–4.PubMedGoogle Scholar
  61. 61.
    Akbaraly TN, Favier A, Berr C. Total plasma carotenoids and mortality in the elderly: results of the Epidemiology of Vascular Ageing (EVA) study. Br J Nutr. 2009;101:86–92.PubMedGoogle Scholar
  62. 62.
    Calabrese V, Stella AM, Butterfield DA, Scapagnini G. Redox regulation in neurodegeneration and longevity: role of the heme oxygenase and HSP70 systems in brain stress tolerance. Antioxid Redox Signal. 2004;6:895–913.PubMedGoogle Scholar
  63. 63.
    Calabrese V, Signorile A, Cornelius C, et al. Practical approaches to investigate redox regulation of heat shock protein expression and intracellular glutathione redox state. Methods Enzymol. 2008;441:83–110.PubMedGoogle Scholar
  64. 64.
    Amadio M, Scapagnini G, Laforenza U, et al. Post-transcriptional regulation of HSP70 expression following oxidative stress in SH-SY5Y cells: the potential involvement of the RNA-binding protein HuR. Curr Pharm Des. 2008;14:2651–8.PubMedGoogle Scholar
  65. 65.
    Jin X, Wang R, Xiao C, et al. Serum and lymphocyte levels of heat shock protein 70 in aging: a study in the normal Chinese population. Cell Stress Chaperones. 2004;9:69–75.PubMedCentralPubMedGoogle Scholar
  66. 66.
    Terry DF, Wyszynski DF, Nolan VG, et al. Serum heat shock protein 70 level as a biomarker of exceptional longevity. Mech Ageing Dev. 2006;127:862–8.PubMedCentralPubMedGoogle Scholar
  67. 67.
    Jin ZG, Melaragno MG, Liao DF, et al. Cyclophilin A is a secreted growth factor induced by oxidative stress. Circ Res. 2000;87:789–96.PubMedGoogle Scholar
  68. 68.
    Marks AR. Cellular functions of immunophilins. Physiol Rev. 1996;76:631–49.PubMedGoogle Scholar
  69. 69.
    Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: Part II: Animal and human studies. Circulation. 2003;108:2034–40.PubMedGoogle Scholar
  70. 70.
    Thomas M, Gavrila D, McCormick ML, et al. Deletion of p47phox attenuates angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-deficient mice. Circulation. 2006;114:404–13.PubMedGoogle Scholar
  71. 71.
    Nigro P, Satoh K, O’Dell MR, et al. Cyclophilin A is an inflammatory mediator that promotes atherosclerosis in apolipoprotein E-deficient mice. J Exp Med. 2011;208:53–66.PubMedCentralPubMedGoogle Scholar
  72. 72.
    Satoh K, Matoba T, Suzuki J, et al. Cyclophilin A mediates vascular remodeling by promoting inflammation and vascular smooth muscle cell proliferation. Circulation. 2008;117:3088–98.PubMedCentralPubMedGoogle Scholar
  73. 73.
    Satoh K, Nigro P, Matoba T, et al. Cyclophilin A enhances vascular oxidative stress and the development of angiotensin II-induced aortic aneurysms. Nat Med. 2009;15:649–56.PubMedCentralPubMedGoogle Scholar
  74. 74.
    Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension. 2007;49:241–8.PubMedGoogle Scholar
  75. 75.
    Suzuki J, Jin ZG, Meoli DF, et al. Cyclophilin A is secreted by a vesicular pathway in vascular smooth muscle cells. Circ Res. 2006;98:811–7.PubMedGoogle Scholar
  76. 76.
    Wang YX, Martin-McNulty B, da Cunha V, et al. Fasudil, a Rho-kinase inhibitor, attenuates angiotensin II-induced abdominal aortic aneurysm in apolipoprotein E-deficient mice by inhibiting apoptosis and proteolysis. Circulation. 2005;111:2219–26.PubMedGoogle Scholar
  77. 77.
    Higashi M, Shimokawa H, Hattori T, et al. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ Res. 2003;93:767–75.PubMedGoogle Scholar
  78. 78.
    Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol. 2005;25:1767–75.PubMedGoogle Scholar
  79. 79.
    Pennesi G, Liu Z, Ciubotariu R, et al. TCR repertoire of suppressor CD8+CD28− T cell populations. Hum Immunol. 1999;60:291–304.PubMedGoogle Scholar
  80. 80.
    Franceschi C, Capri M, Monti D, et al. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev. 2007;128:2–105.Google Scholar
  81. 81.
    Rifai N, Ridker PM. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem. 2001;47:403–11.PubMedGoogle Scholar
  82. 82.
    Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998;279:1477–82.PubMedGoogle Scholar
  83. 83.
    Ridker PM, Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation. 2004;109:1955–9.PubMedGoogle Scholar
  84. 84.
    Danesh J, Muir J, Wong YK, et al. Risk factors for coronary heart disease and acute-phase proteins. A population-based study. Eur Heart J. 1999;20:954–9.PubMedGoogle Scholar
  85. 85.
    Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case–control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol. 1996;144:537–47.PubMedGoogle Scholar
  86. 86.
    Koenig W, Khuseyinova N, Baumert J, et al. Increased concentrations of C-reactive protein and IL-6 but not IL-18 are independently associated with incident coronary events in middle-aged men and women: results from the MONICA/KORA Augsburg case-cohort study, 1984–2002. Arterioscler Thromb Vasc Biol. 2006;26:2745–51.PubMedGoogle Scholar
  87. 87.
    Ferrucci L, Harris TB, Guralnik JM, et al. Serum IL-6 level and the development of disability in older persons. J Am Geriatr Soc. 1999;47:639–46.PubMedGoogle Scholar
  88. 88.
    Weaver JD, Huang MH, Albert M, et al. Interleukin-6 and risk of cognitive decline: MacArthur studies of successful aging. Neurology. 2002;59:371–8.PubMedGoogle Scholar
  89. 89.
    Harris TB, Ferrucci L, Tracy RP, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med. 1999;106:506–12.PubMedGoogle Scholar
  90. 90.
    Kiechl S, Egger G, Mayr M, et al. Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation. 2001;103:1064–70.PubMedGoogle Scholar
  91. 91.
    Patel P, Carrington D, Strachan DP, et al. Fibrinogen: a link between chronic infection and coronary heart disease. Lancet. 1994;343:1634–5.PubMedGoogle Scholar
  92. 92.
    Fried LP, Kronmal RA, Newman AB, et al. Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study. JAMA. 1998;279:585–92.PubMedGoogle Scholar
  93. 93.
    Perry RT, Collins JS, Wiener H, et al. The role of TNF and its receptors in Alzheimer’s disease. Neurobiol Aging. 2001;22:873–83.PubMedGoogle Scholar
  94. 94.
    Lio D, Annoni G, Licastro F, et al. Tumor necrosis factor-α-308A/G polymorphism is associated with age at onset of Alzheimer’s disease. Mech Ageing Dev. 2006;127:567–71.PubMedGoogle Scholar
  95. 95.
    Bruunsgaard H, Skinhøj P, Pedersen AN, et al. Ageing, tumour necrosis factor-α (TNF-α) and atherosclerosis. Clin Exp Immunol. 2000;121:255–60.PubMedCentralPubMedGoogle Scholar
  96. 96.
    Hotamisligil GS, Spiegelman BM. Tumor necrosis factor α: a key component of the obesity-diabetes link. Diabetes. 1994;43:1271–8.PubMedGoogle Scholar
  97. 97.
    Sairanen T, Carpén O, Karjalainen-Lindsberg ML, et al. Evolution of cerebral tumor necrosis factor-alpha production during human ischemic stroke. Stroke. 2001;32:1750–8.PubMedGoogle Scholar
  98. 98.
    Reuben DB, Ix JH, Greendale GA, Seeman TE. The predictive value of combined hypoalbuminemia and hypocholesterolemia in high functioning community-dwelling older persons: MacArthur Studies of Successful Aging. J Am Geriatr Soc. 1999;47:402–26.PubMedGoogle Scholar
  99. 99.
    Reuben DB, Cheh AL, Harris TB, et al. Peripheral blood markers of inflammation predict mortality and functional decline in high-functioning community-dwelling older persons. J Am Geriatr Soc. 2002;50:638–44.PubMedGoogle Scholar
  100. 100.
    Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem. 1999;265:501–23.PubMedGoogle Scholar
  101. 101.
    Zhang N, Ahsan MH, Purchio AF, West DB. Serum amyloid A-luciferase transgenic mice: response to sepsis, acute arthritis, and contact hypersensitivity and the effects of proteasome inhibition. J Immunol. 2005;174:8125–34.PubMedGoogle Scholar
  102. 102.
    Mahmoudi M, Curzen N, Gallagher PJ. Atherogenesis: the role of inflammation and infection. Histopathology. 2007;50:535–46.PubMedGoogle Scholar
  103. 103.
    Blum A, Peleg A, Weinberg M. Anti-cytomegalovirus (CMV) IgG antibody titer in patients with risk factors to atherosclerosis. Clin Exp Med. 2003;3:157–60.PubMedGoogle Scholar
  104. 104.
    Shen YH, Utama B, Wang J, et al. Human cytomegalovirus causes endothelial injury through the ataxia telangiectasia mutant and p53 DNA damage signaling pathways. Circ Res. 2004;94:1310–7.PubMedCentralPubMedGoogle Scholar
  105. 105.
    Aiello AE, Haan M, Blythe L, et al. The influence of latent viral infection on rate of cognitive decline over 4 years. J Am Geriatr Soc. 2006;54:1046–54.PubMedGoogle Scholar
  106. 106.
    Peres A, Bauer M, da Cruz IB, et al. Immunophenotyping and T-cell proliferative capacity in a healthy aged population. Biogerontology. 2003;4:289–96.PubMedGoogle Scholar
  107. 107.
    DelaRosa O, Pawelec G, Peralbo E, et al. Immunological biomarkers of ageing in man: changes in both innate and adaptive immunity are associated with health and longevity. Biogerontology. 2006;7:471–81.PubMedGoogle Scholar
  108. 108.
    Ferguson FG, Wikby A, Maxson P, et al. Immune parameters in a longitudinal study of a very old population of Swedish people: a comparison between survivors and nonsurvivors. J Gerontol A Biol Sci Med Sci. 1995;50:B378–82.PubMedGoogle Scholar
  109. 109.
    Pawelec G, Akbar A, Caruso C, et al. Human immunosenescence: is it infectious? Immunol Rev. 2005;205:257–68.PubMedGoogle Scholar
  110. 110.
    Listì F, Candore G, Modica MA, et al. A study of serum immunoglobulin levels in elderly persons that provides new insights into B cell immunosenescence. Ann NY Acad Sci. 2006;1089:487–95.PubMedGoogle Scholar
  111. 111.
    Colonna-Romano G, Bulati M, Aquino A, et al. B cell immunosenescence in the elderly and in centenarians. Rejuvenation Res. 2008;11:433–9.PubMedGoogle Scholar
  112. 112.
    Ogata K, An E, Shioi Y, et al. Association between natural killer cell activity and infection in immunologically normal elderly people. Clin Exp Immunol. 2001;124:392–7.PubMedCentralPubMedGoogle Scholar
  113. 113.
    Larbi A, Franceschi C, Mazzatti D, et al. Aging of the immune system as a prognostic factor for human longevity. Physiology (Bethesda). 2008;23:64–74.Google Scholar
  114. 114.
    Cevenini E, Invidia L, Lescai F, et al. Human models of aging and longevity. Expert Opin Biol Ther. 2008;8:1393–405.PubMedGoogle Scholar
  115. 115.
    Vijg J, Campisi J. Puzzles, promises and a cure for ageing. Nature. 2008;454:1065–71.PubMedCentralPubMedGoogle Scholar
  116. 116.
    Schmitz KH, Schreiner PJ, Jacobs DR, et al. Independent and interactive effects of apolipoprotein E phenotype and cardiorespiratory fitness on plasma lipids. Ann Epidemiol. 2001;11:94–103.PubMedGoogle Scholar
  117. 117.
    Evans DA, Beckett LA, Field TS, et al. Apolipoprotein E ε4 and incidence of Alzheimer disease in a community population of older persons. JAMA. 1997;277:822–4.PubMedGoogle Scholar
  118. 118.
    Lunetta KL, D’Agostino Sr RB, Karasik D, et al. Genetic correlates of longevity and selected age-related phenotypes: a genome-wide association study in the Framingham Study. BMC Med Genet. 2007;8 Suppl 1:S13.PubMedCentralPubMedGoogle Scholar
  119. 119.
    Kritchevsky SB, Nicklas BJ, Visser M, et al. Angiotensin-converting enzyme insertion/deletion genotype, exercise, and physical decline. JAMA. 2005;294:691–8.PubMedGoogle Scholar
  120. 120.
    Narain Y, Yip A, Murphy T, et al. The ACE gene and Alzheimer’s disease susceptibility. J Med Genet. 2000;37:695–7.PubMedGoogle Scholar
  121. 121.
    Frederiksen H, Gaist D, Bathum L, et al. Angiotensin I-converting enzyme (ACE) gene polymorphism in relation to physical performance, cognition and survival–a follow-up study of elderly Danish twins. Ann Epidemiol. 2003;13:57–65.PubMedGoogle Scholar
  122. 122.
    Bladbjerg EM, Andersen-Ranberg K, de Maat MP, et al. Longevity is independent of common variations in genes associated with cardiovascular risk. Thromb Haemost. 1999;82:1100–5.PubMedGoogle Scholar
  123. 123.
    Blanché H, Cabanne L, Sahbatou M, Thomas G. A study of French centenarians: are ACE and APOE associated with longevity? C R Acad Sci III. 2001;324:129–35.PubMedGoogle Scholar
  124. 124.
    Reynolds CA, Jansson M, Gatz M, Pedersen NL. Longitudinal change in memory performance associated with HTR2A polymorphism. Neurobiol Aging. 2006;27:150–4.PubMedGoogle Scholar
  125. 125.
    d’Adda di Fagagna F, Teo SH, Jackson SP. Functional links between telomeres and proteins of the DNA-damage response. Genes Dev. 2004;18:1781–99.PubMedGoogle Scholar
  126. 126.
    Cherif H, Tarry JL, Ozanne SE, Hales CN. Ageing and telomeres: a study into organ- and gender-specific telomere shortening. Nucleic Acids Res. 2003;31:1576–83.PubMedCentralPubMedGoogle Scholar
  127. 127.
    von Zglinicki T. Oxidative stress shortens telomeres. Trends Biochem Sci. 2002;27:339–44.Google Scholar
  128. 128.
    Bischoff C, Petersen HC, Graakjaer J, et al. No association between telomere length and survival among the elderly and oldest old. Epidemiology. 2006;17:190–4.PubMedGoogle Scholar
  129. 129.
    de Lange T. Protection of mammalian telomeres. Oncogene. 2002;21:532–40.PubMedGoogle Scholar
  130. 130.
    Campisi J, d’Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol. 2007;8:729–40.PubMedGoogle Scholar
  131. 131.
    von Zglinicki T, Martin-Ruiz CM. Telomeres as biomarkers for ageing and age-related diseases. Curr Mol Med. 2005;5:197–203.Google Scholar
  132. 132.
    Martin-Ruiz CM, Gussekloo J, van Heemst D, et al. Telomere length in white blood cells is not associated with morbidity or mortality in the oldest old: a population-based study. Aging Cell. 2005;4:287–90.PubMedGoogle Scholar
  133. 133.
    Calleja M, Peña P, Ugalde C, et al. Mitochondrial DNA remains intact during Drosophila aging, but the levels of mitochondrial transcripts are significantly reduced. J Biol Chem. 1993;268:18891–7.PubMedGoogle Scholar
  134. 134.
    Crawford DR, Wang Y, Schools GP, et al. Down-regulation of mammalian mitochondrial RNAs during oxidative stress. Free Radic Biol Med. 1997;22:551–9.PubMedGoogle Scholar
  135. 135.
    Johnson SR. Menopause and hormone replacement therapy. Med Clin North Am. 1998;82:297–320.PubMedGoogle Scholar
  136. 136.
    Chahal HS, Drake WM. The endocrine system and ageing. J Pathol. 2007;211:173–80.PubMedGoogle Scholar
  137. 137.
    Brochier ML, Arwidson P. Coronary heart disease risk factors in women. Eur Heart J. 1998;19(Suppl A):A45–52.PubMedGoogle Scholar
  138. 138.
    Paganini-Hill A, Corrada MM, Kawas CH. Increased longevity in older users of postmenopausal estrogen therapy: the Leisure World Cohort Study. Menopause. 2006;13:12–8.PubMedCentralPubMedGoogle Scholar
  139. 139.
    Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–33.PubMedGoogle Scholar
  140. 140.
    Gray A, Feldman HA, McKinlay JB, Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 1991;73:1016–25.PubMedGoogle Scholar
  141. 141.
    Araujo AB, Kupelian V, Page ST, et al. Sex steroids and all-cause and cause-specific mortality in men. Arch Intern Med. 2007;167:1252–60.PubMedGoogle Scholar
  142. 142.
    Wang C, Cunningham G, Dobs A, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 2004;89:2085–98.PubMedGoogle Scholar
  143. 143.
    Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med. 2004;34:513–54.PubMedGoogle Scholar
  144. 144.
    Corpas E, Harman SM, Blackman MR. Human growth hormone and human aging. Endocr Rev. 1993;14:20–39.PubMedGoogle Scholar
  145. 145.
    Brown-Borg HM, Rakoczy SG. Catalase expression in delayed and premature aging mouse models. Exp Gerontol. 2000;35:199–212.PubMedGoogle Scholar
  146. 146.
    Hauck SJ, Bartke A. Free radical defenses in the liver and kidney of human growth hormone transgenic mice: possible mechanisms of early mortality. J Gerontol A Biol Sci Med Sci. 2001;56:B153–62.PubMedGoogle Scholar
  147. 147.
    Brown-Borg HM. Hormonal regulation of longevity in mammals. Ageing Res Rev. 2007;6:28–45.PubMedCentralPubMedGoogle Scholar
  148. 148.
    Hoffman AR, Kuntze JE, Baptista J, et al. Growth hormone (GH) replacement therapy in adult-onset GH deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89:2048–56.PubMedGoogle Scholar
  149. 149.
    Serri O, St-Jacques P, Sartippour M, Renier G. Alterations of monocyte function in patients with growth hormone (GH) deficiency: effect of substitutive GH therapy. J Clin Endocrinol Metab. 1999;84:58–63.PubMedGoogle Scholar
  150. 150.
    Yakar S, Setser J, Zhao H, et al. Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. J Clin Invest. 2004;113:96–105.PubMedCentralPubMedGoogle Scholar
  151. 151.
    Tatar M, Kopelman A, Epstein D, et al. A mutant Drosophila insulin receptor homolog that extends life-span and impairs neuroendocrine function. Science. 2001;292:107–10.PubMedGoogle Scholar
  152. 152.
    Accili D, Drago J, Lee EJ, et al. Early neonatal death in mice homozygous for a null allele of the insulin receptor gene. Nat Genet. 1996;12:106–9.PubMedGoogle Scholar
  153. 153.
    Florini JR, Ewton DZ, Coolican SA. Growth hormone and the insulin-like growth factor system in myogenesis. Endocr Rev. 1996;17:481–517.PubMedGoogle Scholar
  154. 154.
    Janssen JA, Stolk RP, Pols HA, et al. Serum total IGF-I, free IGF-I, and IGFB-1 levels in an elderly population: relation to cardiovascular risk factors and disease. Arterioscler Thromb Vasc Biol. 1998;18:277–82.PubMedGoogle Scholar
  155. 155.
    Cappola AR, Xue QL, Ferrucci L, et al. Insulin-like growth factor I and interleukin-6 contribute synergistically to disability and mortality in older women. J Clin Endocrinol Metab. 2003;88:2019–25.PubMedGoogle Scholar
  156. 156.
    Saydah S, Graubard B, Ballard-Barbash R, Berrigan D. Insulin-like growth factors and subsequent risk of mortality in the United States. Am J Epidemiol. 2007;166:518–26.PubMedGoogle Scholar
  157. 157.
    Henry J. Coronary heart disease and arousal of the adrenal cortical axis. In: Dembroski TM, Schmidt TH, Blumchen G, editors. Biobehavioral bases of coronary heart disease. Basel: Karger; 1983. p. 365–81.Google Scholar
  158. 158.
    Lupien S, Lecours AR, Lussier I, et al. Basal cortisol levels and cognitive deficits in human aging. J Neurosci. 1994;14:2893–903.PubMedGoogle Scholar
  159. 159.
    Greendale GA, Unger JB, Rowe JW, Seeman TE. The relation between cortisol excretion and fractures in healthy older people: results from the MacArthur studies-Mac. J Am Geriatr Soc. 1999;47:799–803.PubMedGoogle Scholar
  160. 160.
    Labrie F, Bélanger A, Simard J, et al. DHEA and peripheral androgen and estrogen formation: intracinology. Ann NY Acad Sci. 1995;774:16–28.PubMedGoogle Scholar
  161. 161.
    Migeon CJ, Keller AR, Lawrence B, Shepard II TH. Dehydroepiandrosterone and androsterone levels in human plasma: effect of age and sex; day-to-day and diurnal variations. J Clin Endocrinol Metab. 1957;17:1051–62.PubMedGoogle Scholar
  162. 162.
    Berr C, Lafont S, Debuire B, et al. Relationships of dehydroepiandrosterone sulfate in the elderly with functional, psychological, and mental status, and short-term mortality: a French community-based study. Proc Natl Acad Sci USA. 1996;93:13410–5.PubMedGoogle Scholar
  163. 163.
    Beer NA, Jakubowicz DJ, Matt DW, et al. Dehydroepiandrosterone reduces plasma plasminogen activator inhibitor type 1 and tissue plasminogen activator antigen in men. Am J Med Sci. 1996;311:205–10.PubMedGoogle Scholar
  164. 164.
    Feldman HA, Johannes CB, McKinlay JB, Longcope C. Low dehydroepiandrosterone sulfate and heart disease in middle-aged men: cross-sectional results from the Massachusetts Male Aging Study. Ann Epidemiol. 1998;8:217–28.PubMedGoogle Scholar
  165. 165.
    Cappola AR, Xue QL, Walston JD, et al. DHEAS levels and mortality in disabled older women: the Women’s Health and Aging Study I. J Gerontol A Biol Sci Med Sci. 2006;61:957–62.PubMedCentralPubMedGoogle Scholar
  166. 166.
    Gürlek A, Gedik O. Endogenous sex steroid, GH and IGF-I levels in normal elderly men: relationships with bone mineral density and markers of bone turnover. J Endocrinol Invest. 2001;24:408–14.PubMedGoogle Scholar
  167. 167.
    Svec F, Lopez A. Antiglucocorticoid actions of dehydroepiandrosterone and low concentrations in Alzheimer’s disease. Lancet. 1989;2:1335–6.PubMedGoogle Scholar
  168. 168.
    Nair KS, Rizza RA, O’Brien P, et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med. 2006;355:1647–59.PubMedGoogle Scholar
  169. 169.
    Zoico E, Zamboni M, Zamboni V, et al. Leptin physiology and pathophysiology in the elderly. Adv Clin Chem. 2006;41:123–66.Google Scholar
  170. 170.
    Schautz B, Later W, Heller M, et al. Impact of age on leptin and adiponectin independent of adiposity. Br J Nutr. 2012;108:363–70.PubMedGoogle Scholar
  171. 171.
    De Solis AJ, Fernández-Agulló T, Garcia-SanFrutos M, et al. Impairment of skeletal muscle insulin action with aging in Wistar rats: role of leptin and caloric restriction. Mech Ageing Dev. 2012;133:306–16.PubMedGoogle Scholar
  172. 172.
    Arai Y, Takayama M, Abe Y, Hirose N. Adipokines and aging. J Atheroscler Thromb. 2011;18:545–50.PubMedGoogle Scholar
  173. 173.
    Kmiec Z. Aging and peptide control of food intake. Curr Protein Pept Sci. 2011;12:271–9.PubMedGoogle Scholar
  174. 174.
    Van Gaal LF, Wauters MA, Mertens IL, et al. Clinical endocrinology of human leptin. Int J Obes Relat Metab Disord. 1999;23 Suppl 1:29–36.PubMedGoogle Scholar
  175. 175.
    Margetic S, Gazzola C, Pegg GG, Hill RA. Leptin: a review of its peripheral actions and interactions. Int J Obes Relat Metab Disord. 2002;11:1407–33.Google Scholar
  176. 176.
    Goldstein DS. Plasma catecholamines in clinical studies of cardiovascular diseases. Acta Physiol Scand Suppl. 1984;527:39–41.PubMedGoogle Scholar
  177. 177.
    Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–39.PubMedGoogle Scholar
  178. 178.
    Boldt J, Menges T, Kuhn D, et al. Alterations in circulating vasoactive substances in the critically ill–a comparison between survivors and non-survivors. Intensive Care Med. 1995;21:218–25.PubMedGoogle Scholar
  179. 179.
    Semeraro C, Marchini F, Ferlenga P, et al. The role of dopaminergic agonists in congestive heart failure. Clin Exp Hypertens. 1997;19:201–15.PubMedGoogle Scholar
  180. 180.
    Reuben DB, Talvi SL, Rowe JW, Seeman TE. High urinary catecholamine excretion predicts mortality and functional decline in high-functioning, community-dwelling older persons: MacArthur Studies of Successful Aging. J Gerontol A Biol Sci Med Sci. 2000;55:M618–24.PubMedGoogle Scholar
  181. 181.
    Arnesen E, Refsum H, Bønaa KH, et al. Serum total homocysteine and coronary heart disease. Int J Epidemiol. 1995;24:704–9.PubMedGoogle Scholar
  182. 182.
    Verhoef P, Stampfer MJ, Buring JE, et al. Homocysteine metabolism and risk of myocardial infarction: relation with vitamins B6, B12, and folate. Am J Epidemiol. 1996;143:845–59.PubMedGoogle Scholar
  183. 183.
    Riggs KM, Spiro III A, Tucker K, Rush D. Relations of vitamin B-12, vitamin B-6, folate, and homocysteine to cognitive performance in the Normative Aging Study. Am J Clin Nutr. 1996;63:306–14.PubMedGoogle Scholar
  184. 184.
    Jacques PF, Selhub J, Bostom AG, et al. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med. 1999;340:1449–54.PubMedGoogle Scholar
  185. 185.
    Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350:757–64.PubMedGoogle Scholar
  186. 186.
    SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255–64.Google Scholar
  187. 187.
    Franklin SS, Larson MG, Khan SA, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation. 2001;103:1245–9.PubMedGoogle Scholar
  188. 188.
    Nichols WW, Nicolini FA, Pepine CJ. Determinants of isolated systolic hypertension in the elderly. J Hypertens Suppl. 1992;10:S73–7.PubMedGoogle Scholar
  189. 189.
    Benetos A, Safar M, Rudnichi A, et al. Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. Hypertension. 1997;30:1410–5.PubMedGoogle Scholar
  190. 190.
    Gillum RF, Makuc DM, Feldman JJ. Pulse rate, coronary heart disease, and death: the NHANES I Epidemiologic Follow-up Study. Am Heart J. 1991;121:172–7.PubMedGoogle Scholar
  191. 191.
    Seeman TE, Singer BH, Rowe JW, et al. Price of adaptation–allostatic load and its health consequences. MacArthur studies of successful aging. Arch Intern Med. 1997;157:2259–68.PubMedGoogle Scholar
  192. 192.
    Lapidus L, Bengtsson C, Larsson B, et al. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden. Br Med J. 1984;289:1257–61.Google Scholar
  193. 193.
    Folsom AR, Kaye SA, Sellers TA, et al. Body fat distribution and 5-year risk of death in older women. JAMA. 1993;269:483–7.PubMedGoogle Scholar
  194. 194.
    McKeigue PM, Shah B, Marmot MG. Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians. Lancet. 1991;337:382–6.PubMedGoogle Scholar
  195. 195.
    Felson DT, Zhang Y, Anthony JM, et al. Weight loss reduces the risk for symptomatic knee osteoarthritis in women. The Framingham Study. Ann Intern Med. 1992;116:535–9.PubMedGoogle Scholar
  196. 196.
    Davison KK, Ford ES, Cogswell ME, Dietz WH. Percentage of body fat and body mass index are associated with mobility limitations in people aged 70 and older from NHANES III. J Am Geriatr Soc. 2002;50:1802–9.PubMedGoogle Scholar
  197. 197.
    Himes C. Obesity, disease, and functional limitation in later life. Demography. 2000;37:73–82.PubMedGoogle Scholar
  198. 198.
    de Koning L, Merchant AT, Pogue J, Anand SS. Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies. Eur Heart J. 2007;28:850–6.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Nirankar S. Neki
    • 1
  • Paramjit S. Tappia
    • 2
  • Naranjan S. Dhalla
    • 3
  1. 1.Department of Internal MedicineGovernment Medical College and Guru Nanak Dev HospitalAmritsarIndia
  2. 2.Office of Clinical Research, Asper Clinical Research Institute, St. Boniface Hospital ResearchWinnipegCanada
  3. 3.Department of Physiology, Faculty of MedicineInstitute of Cardiovascular Sciences, University of Manitoba, St. Boniface Hospital ResearchWinnipegCanada

Personalised recommendations